Genotypic and phenotypic alterations in Epstein–Barr virus‐associated lymphoma

Ohshima, Koichi; Suzumiya, Junji; Kanda, Motonobu; Haraoka, Seiji; Kawasaki, Chika; Shimazaki, Kae; Kikuchi, Masahiro

doi:10.1046/j.1365-2559.1999.00784.x

Cited by 14 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…27 Immunophenotypically, and although of B-cell origin, PEL cells express leukocyte common antigen (CD45) and post-germinal center B cell/plasma cell-associated antigens (CD38, CD138) suggesting a late stage of B-cell differentiation, 28, 29 but classic B-cell markers (CD19, CD20, CD79a) and T-cell markers (CD3, CD4, CD8) are absent. 29, 30, 31 In more detail and among 61 cases of PEL reported in the literature, 93% were CD45 positive, 73% were CD30 positive, and finally, T- and B-cell markers were expressed in 4.9 and 1.6%, respectively. 32 The HHV8 gene expression pattern in PEL cells is mostly latent with expression of LANA-1/2, kaposin and cellular homologs such as v-cyclin, v-FLIP, and to a lesser extent v-IL-6 (ref.…”

Section: Diagnosis Of Pelmentioning

confidence: 95%

Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature

Antar

Hajj

Jabbour

et al. 2014

Blood Cancer Journal

View full text Add to dashboard Cite

Primary effusion lymphoma (PEL) is a rare aggressive subset of non-Hodgkin B-cell lymphoma. It is caused by Kaposi sarcoma-associated herpesvirus/human herpesvirus type 8 (KSHV/HHV8). It occurs mainly, but not exclusively, in HIV-positive patients. PEL predominantly develops in serous cavities and occasionally in extracavitary regions. PEL carries a very poor prognosis with a median survival time of <6 months. Indeed, currently used treatment modalities such as CHOP chemotherapy are far from achieving complete and sustainable remission. Therefore, there is no clear standard of care established in the treatment of PEL patients, stressing the need for novel-targeted approaches. Here, we have attempted a comprehensive assessment of the treatment of PEL, discussed avant-garde therapies and updated the state of preclinical research with promising clinical applications in the field. These include inhibitors of viral replication, modulators of cell signaling and inflammation, nuclear factor kappa B (NF-κB) and histone deacetylase inhibitors, and recently the combination of arsenic trioxide and interferon-alpha. Some of these targeted therapies have not yet reached clinical studies, although others were used in a few individual case reports with low numbers of patients. We also describe the first case of a 77-year-old, HIV-negative, HHV8-positive patient diagnosed with PEL limited to the pleural and peritoneal cavities. He received lenalidomide 25 mg/day for 21 days every 28 days. Treatment was well tolerated with no side effects. He rapidly improved after 1 month of treatment and progressively achieved complete remission persistent after 18 months of therapy. We believe that this review will bridge an important gap between classical chemotherapy and modern approaches of targeted therapy. Finally, our findings warrant further evaluation of lenalidomide in future prospective clinical studies.

show abstract

Section: Diagnosis Of Pelmentioning

confidence: 95%

Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature

Antar

Hajj

Jabbour

et al. 2014

Blood Cancer Journal

View full text Add to dashboard Cite

show abstract

“…The EBNA 2A and 2B primer sequences for EBV subtyping, previously reported by Ohshima et al [22], were used for DNA amplification (listed in Table 1). The final reaction was incubated at 95°C for 10 min, followed by 50 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. Then, a final extension at 72°C for 10 minutes was performed.…”

Section: Methodsmentioning

confidence: 99%

Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand

et al. 2011

View full text Add to dashboard Cite

BackgroundExtranodal NK/T-cell lymphoma, nasal type (ENKTL) is not common worldwide, but it is the most common T- and NK-cell lymphomas in many Asian countries. Immunophenotypic profiles were studied based on limited series. The authors, therefore, studied on ENKTL according to characterize immunophenotypic profiles as well as the distribution of EBV subtype and LMP-1 gene deletion.MethodsBy using tissue microarray (TMA), immunohistochemical study and EBV encoded RNA (EBER) in situ hybridization were performed. T-cell receptor (TCR) gene rearrangement, EBV subtyping, and LMP-1 gene deletion were studied on the available cases.ResultsThere were 22 cases eligible for TMA. ENKTL were positive for CD3 (91%), CD5 (9%), CD7 (32%), CD4 (14%), CD56 (82%), TIA-1 (100%), granzyme B (95%), perforin (86%), CD45 (83%), CD30 (75%), Oct2 (25%), and IRF4/MUM1 (33%). None of them was positive for βF1, CD8, or CD57. TCR gene rearrangement was negative in all 18 tested cases. EBV was subtype A in all 15 tested cases, with 87% deleted LMP-1 gene. Cases lacking perforin expression demonstrated a significantly poorer survival outcome (p = 0.008).ConclusionsThe present study demonstrated TIA-1 and EBER as the two most sensitive markers. There were a few CD3 and/or CD56 negative cases noted. Interestingly, losses of CD45 and/or CD7 were not uncommon while Oct2 and IRF4/MUM1 could be positive in a subset of cases. Based on the present study in conjunction with the literature review, determination of PCR-based TCR gene rearrangement analysis might not be a useful technique for making diagnosis of ENKTL.

show abstract

“…Although many cases will contain monoclonal Ig sequences, some cases appear Ig negative. EBV often interferes with the ability of a cell to produce Ig and also leads to the downregulation of other B-cell associated antigens (48).…”

Section: Extranodal Lymphomas Of the Sinonasal And Oral Regionsmentioning

confidence: 99%

Lymphoid Lesions of the Head and Neck: A Model of Lymphocyte Homing and Lymphomagenesis

Jaffe

2002

Modern Pathology

View full text Add to dashboard Cite

Genotypic and phenotypic alterations in Epstein–Barr virus‐associated lymphoma

Abstract: We report the genotypic and/or phenotypic alterations in four patients with EBV-associated lymphoma/leukaemia. However, EBV genotype did not change in all four. These findings suggest that EBV might induce the cell marker and lineage alteration in vivo, as in vitro.

Cited by 14 publications

References 33 publications

Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature

Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature

Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand

Lymphoid Lesions of the Head and Neck: A Model of Lymphocyte Homing and Lymphomagenesis

Contact Info

Product

Resources

About